Clinical trials: Bacterial Disease Carrier
Mycobacterium Avium-intracellulare Infection, HIV Infections
Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048
Some people who have taken azithromycin to prevent MAC (Mycobacterium avium Complex, a bacterial infection common in HIV-infected persons) have been found to carry antibiotic-resistant bacteria (germs that grow despite the…
- Conditions
- Mycobacterium Avium-intracellulare Infection, HIV Infections, Pneumococcal Infections
- Trial name
- NCT00000933
- Where
- 15 sites in United States
- Volunteers
- 326 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Typhoid Fever
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)
This trial is aimed to evaluate the safety and immunogenicity profiles of a new Vi-CRM197 conjugate vaccine against S. Typhi in healthy human adults in comparison with the currently licensed Vi polysaccharide vaccine.
- Trial name
- NCT01123941
- Testing
- Typherix, NVGH Vi-CRM197
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Novartis
Enterobacteriaceae Infections
Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.
Antimicrobial resistance is a major threat worldwide and now concerns last-ressource antibiotics such as carbapenems. As the resistance to carbapenems is directly due to their use, their spare has become a public health…
- Trial name
- PROBATAZO (NCT04276480)
- Testing
- Piperacillin-tazobactam
- Where
- 2 sites in France
- Volunteers
- 9 people
- Sponsor
- University Hospital, Bordeaux
Infectious Disease, Bacterial Infections
Safety & Efficacy of an Antibacterial Protein Molecule Applied Topically to the Nostrils of Volunteers and Patients
The purpose of this study is to determine whether the antibacterial protein P128 is (i) safe and well tolerated in healthy volunteers and in chronic kidney diseases patients on dialysis, (ii) is it effective in reducing the nasal…
- Trial name
- NCT01746654
- Testing
- P128-0.1 mg, P128-0.3 mg, P128-1.0 mg
- Where
- Singapore
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- GangaGen, Inc.
Mastitis, Staphylococcus Aureus
Staphylococcus Aureus Carrier Status in Breastfeeding Mothers and Infants and the Risk of Lactation Mastitis
Lactation (breastfeeding) mastitis is an acute infection of the milk ducts of the breastfeeding woman. Staphylococcus aureus (S. aureus) is the infectious germ most commonly associated with lactation mastitis.
- Conditions
- Mastitis, Staphylococcus Aureus, Staphylococcal Infections
- Trial name
- NCT00620984
- Where
- United States
- Volunteers
- 557 people
- Sponsor
- State University of New York - Upstate Medical University
Bacterial Infections
Impact of a Carrier (Infection, Colonization) of Highly Bacteria Resistance on the Patient's Quality of Life Hospital Environment
The quality of life of carriers detected infected or colonized by emerging highly resistant bacteria (BHRe) following the implementation of specific hygiene measures during the discovery of the microorganism has been little…
- Trial name
- QALYBHRe (NCT04226001)
- Testing
- Quality of life questionnaire
- Sponsor
- Hospices Civils de Lyon
Helicobacter Infections, Urinary Tract Infection
First Time in Man Study of Finafloxacin Hydrochloride
The purpose of this study is to study the safety of single doses and multiple doses of Finafloxacin hydrochloride in healthy volunteers. The level of Finafloxacin hydrochloride will be measured in the subjects blood and urine.
- Trial name
- NCT00483158
- Testing
- Finafloxacin hydrochloride
- Where
- Switzerland
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- MerLion Pharmaceuticals GmbH
Group B Streptococcus Carrier in Childbirth, Group B Streptococcal Infection, Late-Onset
Serosurveillance Study of Maternally Derived Anti-GBS Antibody
Globally, neonatal mortality remains unacceptably high, with little change in the death rate in the first 28 days of life since 1990, despite reductions in under-5 mortality of up to 50% over the same period.
- Conditions
- Group B Streptococcus Carrier in Childbirth, Group B Streptococcal Infection, Late-Onset, Group B Streptococcal Infection, Early-Onset, Group B Streptococcus Neonatal Sepsis
- Trial name
- ProGreSs (NCT04549220)
- Where
- Uganda
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- St George's, University of London
Group B Streptococcus Carrier in Childbirth, Group B Streptococcal Infection, Late-Onset
Maternal, Neonatal and Infant Outcomes at Kawempe National Referral Hospital
Maternal immunisation is an evolving field that deserves special attention given its potential to have a significant positive impact on the health of women and children globally, and the potential safety and risk considerations…
- Conditions
- Group B Streptococcus Carrier in Childbirth, Group B Streptococcal Infection, Late-Onset, Group B Streptococcal Infection, Early-Onset, Group B Streptococcus Neonatal Sepsis
- Trial name
- PREPARE (NCT04653948)
- Where
- Uganda
- Volunteers
- 3,423 people, healthy volunteers welcome
- Sponsor
- St George's, University of London
Bacterial Disease Carrier, Cystic Fibrosis
A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa
This is a phase 1b/2 study of a single dose of intravenous (IV) bacteriophage in males and non-pregnant females, at least 18 years old, diagnosed with Cystic Fibrosis (CF).
- Trial name
- NCT05453578
- Testing
- WRAIR-PAM-CF1
- Where
- 19 sites in United States
- Volunteers
- 73 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Group B Streptococcus Carrier in Childbirth, Group B Streptococcal Infection, Late-Onset
Serocorrelate of Protection Against GBS (PREPARE WP3)
A multicentre, international case-control study to develop a biobank of sera from 150 cases of serotype III GBS disease and associated clinical information from seven countries (Malawi, Uganda, UK, the Netherlands, Italy and…
- Conditions
- Group B Streptococcus Carrier in Childbirth, Group B Streptococcal Infection, Late-Onset, Group B Streptococcal Infection, Early-Onset, Group B Streptococcus Neonatal Sepsis
- Trial name
- NCT04732026
- Where
- 6 sites in France, Italy and 4 more
- Volunteers
- 600 people
- Sponsor
- St George's, University of London
Pseudomonas Aeruginosa, Cystic Fibrosis
The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis
Pseudomonas aeruginosa (Pa) is the bacterium that causes one of the most consequential lung infections in people with CF. Many young children do not have Pa in their lungs but will become infected as they get older.
- Trial name
- NCT01616862
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Zafer Soultan
Gastric (Stomach) Cancer, Helicobacter Infection
An Observational Study for Gastric Cancer in Carriers of High Risk Helicobacter Pylori
This study is intended to be a prospective observational cohort study. The incidence of gastric cancer and progression of gastric precancerous lesions will be compared between groups through prospective follow-up of a population…
- Trial name
- NCT06896370
- Testing
- observational study
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fudan University
Enterobacteriaceae Infections, Carrier State
Study of Probiotic Adjunctive Therapy for Decolonization of Carbapenem-Resistant Enterobacterales
To evaluate the efficacy of probiotic preparations as adjunctive therapy for the decolonization of intestinal carbapenem-resistant organisms (CRO), in comparison with conventional antibiotic therapy alone, with the primary…
- Trial name
- NCT07707869
- Testing
- Probiotic Preparation, Conventional Antibiotic
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Haemophilus Influenzae Type B, Carrier State
Study to Eliminate Hib Carriage in Rural Alaska Native Villages
Hib disease rates in rural Alaska before introduction of HIb conjugate vaccine were among the highest in the world. Since vaccine introduction, rates have fallen by 90% but the disease has not been eliminated.
- Trial name
- NCT00153556
- Testing
- Hib conjugate vaccine (HbOC, Wyeth Vaccines)
- Where
- United States
- Volunteers
- 3,200 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Streptococcal Infections
Long Term Follow-up of Patients With Group A Streptococcal Infection Originating From the Genital Tract
Group A streptococcus (GAS) causes a variety of human infections. It is also an uncommon but serious cause of postpartum infections.
- Trial name
- NCT00299663
- Where
- Israel
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Klebsiella Pneumoniae Carbapenemase Resistant Associated Bacteremia or Pneumonia
A Study Evaluating the Role of Oral Antibiotics in an Aim to Eradicate Carrier State of Carbapenem- Resistant Klebsiella Pneumonia (KPC).
Klebsiella pneumonia, inhabitant of the digestive tract, is a frequent nosocomial pathogen. It is currently the fourth most common cause of pneumonia and fifth most common cause of bacteremia in intensive care patients (1-3).
- Trial name
- NCT01266499
- Testing
- Colistin (Polymyxin E) 100mg x 4/d, both medications, will not receive PO treatment
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Rambam Health Care Campus
Onycomycosis
A Randomized Study to Evaluate the Efficacy of Herbal Ingredients Combined With a Carrier System (Phytonail) Compared With Amorolfine 5% Nail Lacquer (Loceryl) in the Treatment of Toenail Onychomycosis
Background: Onychomycosis, the most common nail disorder, is a superficial fungal infection affecting toenails more than fingernails. Onychomycosis can cause pain and discomfort and has the potential to be a source of morbidity.
- Trial name
- NCT01929187
- Testing
- Phytonail, Loceryl
- Where
- Taiwan
- Volunteers
- 72 people
- Sponsor
- National Taiwan University Hospital